# Core C: Proteogenomics Core

> **NIH NIH P01** · UNIVERSITY OF TEXAS MED BR GALVESTON · 2021 · $331,780

## Abstract

PROTEOGENOMICS CORE (Core C): PROJECT SUMMARY/ABSTRACT
Ebola virus (EBOV) and other filoviruses cause devastating pathology, resulting in large part from a dysregulated
immune response. At present, our characterization of immune cell-specific responses to EBOV is limited. To
address this complex issue, the research projects of this proposal will employ a wide range of OMICS and high-
throughput technologies focused at each stage of the “central dogma”; from RNA synthesis, through RNA
metabolism, to protein translation and modification. The role of the Proteogenomics Core (Core C) will be to
apply cutting-edge massively parallel sequencing and proteomics approaches in support of Research Projects
1, 2, and 3, and to develop novel procedures and technologies to tackle the uniquely complex immune response
to EBOV. We will use a combination of short-read (Illumina) and long-read (Nanopore) approaches to
characterize epigenetic, transcriptional, and posttranscriptional responses to EBOV infection. Output from
sequencing and proteomic analysis will be integrated with the Bioinformatics and Modeling Core (Core D)
and deposited in public databases. Finally, these results will be interpreted together with the original main
Projects.
The Proteogenomics Core comprises a group of experts with experience in the implementation of the wide
range of approaches in molecular biology, experimental design, and downstream computational analyses. Core
C has a well established track record of innovating novel and cutting-edge methodologies in both next-generation
sequencing and mass spectrometry, and can therefore develop and provide state-of-the-art technical support to
advance the proposed research to new frontiers. The core will be directed by Dr. Routh, an expert in applying
novel sequencing technologies to study RNA virus evolution, transcriptomics, and bioinformatics. Drs. Russell
and Widen (Associate Core Leads) are directors of the mass spectrometry and next-generation sequencing
facilities, respectively, at the University of Texas Medical Branch.
The overarching goal of the Proteogenomics Core is to provide a comprehensive and unprecedented
characterization of the “phenome” of cells infected by EBOV, both in cell culture and NHP models. By comparing
changes in the epigenetic landscape to observed perturbations in the transcriptome, we will first determine how
these events are coordinated and subsequently manifest as changes in the host proteome.

## Key facts

- **NIH application ID:** 10188757
- **Project number:** 1P01AI150585-01A1
- **Recipient organization:** UNIVERSITY OF TEXAS MED BR GALVESTON
- **Principal Investigator:** Andrew Laurence Routh
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $331,780
- **Award type:** 1
- **Project period:** 2021-04-15 → 2026-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10188757

## Citation

> US National Institutes of Health, RePORTER application 10188757, Core C: Proteogenomics Core (1P01AI150585-01A1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10188757. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*